FGF21 and metabolic dysfunction-associated steatotic liver disease: As the first meta-analysis to comprehensively and quantitatively evaluate the relationship between noninvasive biomarkers and NAFLD, this study demonstrates that CK-18, FGF-21, and related biomarker panel can be used to diagnose NAFLD, especially NASH.